Rockefeller Capital Management L.P. Invests $205,000 in Xencor, Inc. (NASDAQ:XNCR)

Rockefeller Capital Management L.P. purchased a new position in shares of Xencor, Inc. (NASDAQ:XNCR) in the third quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 10,211 shares of the biopharmaceutical company’s stock, valued at approximately $205,000.

A number of other institutional investors and hedge funds also recently made changes to their positions in XNCR. Quarry LP bought a new stake in shares of Xencor during the 2nd quarter worth approximately $36,000. KBC Group NV lifted its stake in Xencor by 63.5% in the 3rd quarter. KBC Group NV now owns 3,123 shares of the biopharmaceutical company’s stock valued at $63,000 after purchasing an additional 1,213 shares during the last quarter. SG Americas Securities LLC bought a new position in Xencor in the 2nd quarter valued at approximately $154,000. XTX Topco Ltd bought a new position in Xencor in the 2nd quarter valued at approximately $196,000. Finally, Point72 Asia Singapore Pte. Ltd. bought a new position in Xencor in the 2nd quarter valued at approximately $212,000.

Wall Street Analyst Weigh In

Several equities analysts recently commented on the stock. Royal Bank of Canada increased their price objective on shares of Xencor from $31.00 to $34.00 and gave the company an “outperform” rating in a research note on Thursday, September 26th. Piper Sandler raised shares of Xencor from a “neutral” rating to an “overweight” rating and increased their price objective for the company from $20.00 to $30.00 in a research note on Monday, December 2nd. BMO Capital Markets reissued an “outperform” rating and issued a $34.00 price objective (up previously from $32.00) on shares of Xencor in a research note on Friday, November 8th. Wedbush reissued an “outperform” rating and issued a $38.00 price objective on shares of Xencor in a research note on Thursday, November 7th. Finally, JPMorgan Chase & Co. upped their price target on shares of Xencor from $27.00 to $28.00 and gave the company an “overweight” rating in a research report on Thursday, November 7th. One equities research analyst has rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, Xencor has an average rating of “Buy” and an average price target of $36.50.

Insider Transactions at Xencor

In related news, VP John R. Desjarlais sold 68,684 shares of the stock in a transaction on Monday, November 11th. The shares were sold at an average price of $23.48, for a total transaction of $1,612,700.32. Following the transaction, the vice president now directly owns 200,104 shares of the company’s stock, valued at $4,698,441.92. This represents a 25.55 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Alan Bruce Montgomery sold 1,421 shares of the stock in a transaction on Wednesday, December 4th. The stock was sold at an average price of $27.03, for a total transaction of $38,409.63. Following the transaction, the director now directly owns 9,140 shares in the company, valued at approximately $247,054.20. This represents a 13.46 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 136,050 shares of company stock worth $3,277,609 over the last three months. 5.23% of the stock is owned by company insiders.

Xencor Trading Down 0.1 %

Shares of NASDAQ XNCR opened at $25.26 on Thursday. Xencor, Inc. has a 52-week low of $15.31 and a 52-week high of $27.24. The company has a debt-to-equity ratio of 0.01, a quick ratio of 6.23 and a current ratio of 6.23. The firm has a 50 day moving average price of $22.84 and a two-hundred day moving average price of $20.65. The stock has a market cap of $1.77 billion, a P/E ratio of -7.89 and a beta of 0.69.

Xencor (NASDAQ:XNCR) last posted its quarterly earnings data on Wednesday, November 6th. The biopharmaceutical company reported ($0.71) earnings per share for the quarter, topping the consensus estimate of ($0.98) by $0.27. Xencor had a negative net margin of 232.77% and a negative return on equity of 30.92%. The company had revenue of $10.70 million during the quarter, compared to analysts’ expectations of $14.59 million. During the same period in the prior year, the company posted ($0.40) earnings per share. Xencor’s revenue for the quarter was down 81.9% compared to the same quarter last year. As a group, equities analysts forecast that Xencor, Inc. will post -3.71 EPS for the current year.

About Xencor

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.